FDA approves Ozempic to help reduce risk of worsening chronic kidney disease
The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...
RFK Jr. fields pharma questions on Day Two
After two days of making his case to Senate committees, Robert F. Kennedy Jr.’s bid to lead federal health agencies still ...
15 Press Releases You Need to See This Week
With thousands of press releases published each week, it can be difficult to keep up with everything on . To help journalists ...
pharmaphorum12h
Two more biotechs, Metsera and Maze, cross IPO finish line
Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...
Ozempic May Protect Against Alzheimer’s
One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...
The American Journal of Managed Care23h
Suzetrigine: First-in-Class Non-Opiate Pain Therapy is Approved by FDA
Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...